Relion Therapeutics is a clinical-stage precision medicine company developing small-molecule therapies for cancer and genetic diseases using its proprietary Dynamo platform, which applies Motion-Based Drug Design to identify drugs targeting protein dynamics historically difficult to address with conventional approaches. The company's lead candidate, zovegalisib, is an allosteric PI3Kα inhibitor in clinical development for PI3Kα-mutated breast cancer and PIK3CA-driven vascular anomalies, with additional programs targeting NRAS-mutated tumors, Fabry disease, and other oncology indications. Relion plans to generate revenue through a focused U.S. sales organization targeting oncologists and genetic disease specialists, while pursuing distribution partnerships internationally and selectively out-licensing certain programs to strategic partners.